Adoptive cell transfer: a clinical path to effective cancer immunotherapy - PubMed (original) (raw)
Review
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Steven A Rosenberg et al. Nat Rev Cancer. 2008 Apr.
Abstract
Adoptive cell therapy (ACT) using autologous tumour-infiltrating lymphocytes has emerged as the most effective treatment for patients with metastatic melanoma and can mediate objective cancer regression in approximately 50% of patients. The use of donor lymphocytes for ACT is an effective treatment for immunosuppressed patients who develop post-transplant lymphomas. The ability to genetically engineer human lymphocytes and use them to mediate cancer regression in patients, which has recently been demonstrated, has opened possibilities for the extension of ACT immunotherapy to patients with a wide variety of cancer types and is a promising new approach to cancer treatment.
Figures
Figure 1. The generation of anti-tumour T cells used for adoptive cell therapy
A tumour is excised and multiple individual cultures are established, separately grown and assayed for specific tumour recognition. Cultures with high anti-tumour reactivity are expanded to large numbers (>1010 cells) and reinfused into the cancer patient following the administration of a conditioning lymphodepleting chemotherapy. IL2, interleukin 2.
Figure 2. Examples of objective tumour regressions in patients receiving adoptive cell transfer of autologous anti-tumour lymphocytes following a lymphodepleting preparative regimen
In each case the pretreatment scans and photos are shown on the left and the post-treatment on the right. a | A 45-year-old male with metastatic melanoma to the liver (upper) and right adrenal gland (middle) who was refractory to prior treatment with high dose α interferon as well as high-dose interleukin 2 (IL2). He underwent a rapid regression of metastases and developed vitiligo (lower). b | A 55-year-old male with rapid tumour growth in the axilla as well as multiple brain metastases from metastatic melanoma that was refractory to prior treatment with high dose IL2 who underwent rapid regression of nodal and brain metastases.
Figure 3. The steps involved in generating anti-tumour T cells by inserting genes encoding T-cell receptors
Highly avid anti-tumour T cells are identified and the genes encoding their T-cell receptors (TCRs) are cloned and inserted into retroviruses. Retroviral supernatants are then produced under good manufacturing practice (GMP) conditions and used to insert the T-cell receptors into normal lymphocytes. Expression of the T-cell receptor is then compared in untransduced (UnTd) and transduced (Td) cells by fluorescence-activated cell sorting analysis and by recognition in vitro of HLA-A2+ 526 melanoma line and not the HLA-A2− 888 melanoma line. The effector cells were the anti-MART JKF6 line and untransduced (PBL) and transduced (TCR) lymphocytes. C, constant; IRES, internal ribosome entry site; LTR, long terminal repeat; SA, splice acceptor site; SD, splice donor site; V, variable. Steps 3 and 5 reproduced, with permission, from REF. 4 © American Association for the Advancement of Science (2006).
Figure 4. Diagram of the retroviral constructs used to insert T-cell receptor (TCR) genes in T cells
T cells can be engineered with two classes of receptor proteins that are capable of recognizing tumour-associated antigens. Naturally occurring TCRs require coordinated expression of an α and β chain, which can be facilitated by an internal ribosome entry site (IRES) or by the use of a 2A fusion protein. A chimeric antigen receptor is an artificially constructed hybrid protein containing the antigen-binding domains of a single-chain antibody (scFv) linked to T-cell signal domains, such as CD28 and CD3ζ. Vector-specific _cis_-acting sequences are the long terminal repeat (LTR) that contains the enhancer, promoter and polyadenylation sites, splice donor (SD) and splice acceptor (SA) sequences, and packaging signal (ψ). The target antigen for each of these vectors is as indicated.
Timeline 1. Selected highlights in the development of ACT in animal models
ACT, adoptive cell therapy; IL2, interleukin 2; TCR, T-cell receptor.
Timeline 2. Examples of ACT in patients with cancer
EBV, Epstein–Barr virus; PTLD, post-transplant lymphoproliferative disease; TCR, T-cell receptor; TIL, tumour-infiltrating lymphocytes.
Comment in
- Immunotherapy: Vaccine trials in melanoma -- time for reflection.
Eggermont AM. Eggermont AM. Nat Rev Clin Oncol. 2009 May;6(5):256-8. doi: 10.1038/nrclinonc.2009.42. Nat Rev Clin Oncol. 2009. PMID: 19390551
Similar articles
- Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.
Rosenberg SA. Rosenberg SA. Nat Rev Clin Oncol. 2011 Aug 2;8(10):577-85. doi: 10.1038/nrclinonc.2011.116. Nat Rev Clin Oncol. 2011. PMID: 21808266 Free PMC article. Review. - Co-transfer of tumor-specific effector and memory CD8+ T cells enhances the efficacy of adoptive melanoma immunotherapy in a mouse model.
Contreras A, Beems MV, Tatar AJ, Sen S, Srinand P, Suresh M, Luther TK, Cho CS. Contreras A, et al. J Immunother Cancer. 2018 May 29;6(1):41. doi: 10.1186/s40425-018-0358-2. J Immunother Cancer. 2018. PMID: 29843822 Free PMC article. - Cell transfer-based immunotherapies in cancer: A review.
Gorabi AM, Hajighasemi S, Sathyapalan T, Sahebkar A. Gorabi AM, et al. IUBMB Life. 2020 Apr;72(4):790-800. doi: 10.1002/iub.2180. Epub 2019 Oct 21. IUBMB Life. 2020. PMID: 31633881 Review. - Adoptive immunotherapy of cancer: Gene transfer of T cell specificity.
Al-Khami AA, Mehrotra S, Nishimura MI. Al-Khami AA, et al. Self Nonself. 2011 Apr;2(2):80-84. doi: 10.4161/self.2.2.15832. Epub 2011 Apr 1. Self Nonself. 2011. PMID: 22299059 Free PMC article. - The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens.
Rosenberg SA. Rosenberg SA. Annu Rev Med. 1996;47:481-91. doi: 10.1146/annurev.med.47.1.481. Annu Rev Med. 1996. PMID: 8712798 Review.
Cited by
- Towards Targeting Endothelial Rap1B to Overcome Vascular Immunosuppression in Cancer.
Ghadrdoost Nakhchi B, Kosuru R, Chrzanowska M. Ghadrdoost Nakhchi B, et al. Int J Mol Sci. 2024 Sep 12;25(18):9853. doi: 10.3390/ijms25189853. Int J Mol Sci. 2024. PMID: 39337337 Free PMC article. Review. - Nanomedicines in diagnosis and treatment of prostate cancers: an updated review.
Wang J, Zhang X, Xing J, Gao L, Lu H. Wang J, et al. Front Bioeng Biotechnol. 2024 Aug 21;12:1444201. doi: 10.3389/fbioe.2024.1444201. eCollection 2024. Front Bioeng Biotechnol. 2024. PMID: 39318666 Free PMC article. Review. - Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment.
Chang Y, Chang M, Bao X, Dong C. Chang Y, et al. Bioact Mater. 2024 Sep 10;42:379-403. doi: 10.1016/j.bioactmat.2024.08.046. eCollection 2024 Dec. Bioact Mater. 2024. PMID: 39308543 Free PMC article. Review. - From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies.
Gharib E, Robichaud GA. Gharib E, et al. Int J Mol Sci. 2024 Aug 30;25(17):9463. doi: 10.3390/ijms25179463. Int J Mol Sci. 2024. PMID: 39273409 Free PMC article. Review. - Alginate-based artificial antigen presenting cells expand functional CD8+ T cells with memory characteristics for adoptive cell therapy.
Omotoso MO, Est-Witte SE, Shannon SR, Li S, Nair NM, Neshat SY, Kang SS, Tzeng SY, Green JJ, Schneck JP. Omotoso MO, et al. Biomaterials. 2025 Feb;313:122773. doi: 10.1016/j.biomaterials.2024.122773. Epub 2024 Aug 24. Biomaterials. 2025. PMID: 39217794
References
- Rosenberg SA, et al. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report. N. Engl. J. Med. 1988;319:1676–1680.The first paper to demonstrate the regression of cancer using TIL for the immunotherapy of patients with metastatic melanoma.
- Dudley ME, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 2005;23:2346–2357.Reference 2 and Reference 3 demonstrate that lymphodepletion prior to ACT can lead to increased cancer regression as well as clonal repopulation of patients with anti-tumour lymphocytes.
- Morgan RA, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126–129.The first paper demonstrating the adoptive cell transfer of lymphocytes transduced with a retrovirus encoding TCRs that recognize a cancer antigen can mediate anti-tumour responses in patients with metastatic melanoma.
- Rosenberg SA, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 1985;313:1485–1492. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources